Cybin Company Presentation

P r i v a t e & C o n f i d e n t i a l 23 Market Comparables Status Valuation Patents Filed API Clinical Trials Indication Jurisdictions (1) Private US$240mm N/A Arketamine Ibogaine Unknown Depression Anxiety Addiction Berlin New York Amsterdam (2) Public (CSE:SHRM) C$173mm 4 provisional patents under Tassili 7 patents under AltMed Ketamine Psilocybin CBD Pre-Clinical / Phase 1 Treatment Resistant Depression Addiction PTSD/TBI OCD/Anxiety Toronto clinic USA (Expansion) (3) Private US$380mm Granted US Patent No 10,519,175, relating to treating TRD with psilocybin formulation COMP360 Psilocybin Phase 2(b) TRD Treatment Resistant Depression Czech Republic, the Netherlands, Portugal, Spain, the UK, and the USA Go-Public C$70 - 80mm 1 provisional patent Psilocybin Pre-Clinical Depression Addiction Eating Disorders Cognitive Flexibility Canada Jamaica USA Private Unknown Patent filed for treatment of LSD for Alzheimer's Disease LSD Phase 1 Complete Alzheimer's Disease Diabetic Retinopathy London, England New York, USA Go-Public US$50mm Provisional patent filed for FT-104 Ketamine FT-104 (Psilocybin) Pre-Clinical Addiction Depression Toronto clinic NY / LA (Expansion) (2) Public (NEO:MMED) C$147mm Patent filed for technology to reduce LSD effects in therapy 18-MC (Ibogaine) LSD MDMA Phase 1(b) Phase 2 Opioid Addiction ADHD Canada (Parentco) U.S. (18-MC owner) Basel, Switzerland (partnership) Australia (clinical trials) (2) Public (CSE:NUMI) C$43mm N/A N/A N/A N/A Vancouver clinic (Unlicensed) Acquiring more clinics in Canada (1) Valuation per CB Insights estimation as at March 27, 2019. (2) Publicly traded company; valuation as at July 6, 2020. (3) Estimated valuation per publicly available sources.